<DOC>
	<DOCNO>NCT01217229</DOCNO>
	<brief_summary>PLX3397 selective inhibitor Fms , Kit , oncogenic Flt3 activity.The primary objective study evaluate efficacy , measure overall response rate , orally administer PLX3397 patient relapse refractory classical Hodgkin lymphoma ( HL ) . Secondary objective include safety , duration response , disease control rate , progression free survival , drug affect body .</brief_summary>
	<brief_title>Safety Efficacy Study PLX3397 Adults With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>1 . Male female patient ≥18 year old 2 . Pathologic confirmation relapse refractory classical Hodgkin lymphoma , archival fresh tissue available retrospective analysis . 3 . Patients must progress afteror ineligible forautologous stem cell transplantation . Patients receive prior allogeneic stem cell transplantation eligible evidence GVHD immunosuppression least 3 month prior C1D1 . 4 . Documented disease radiographically measurable ( ≥2 cm large transverse dimension ) . 5 . Patients must discontinue previous monoclonal antibody , radioimmunotherapy , cytotoxic chemotherapy least 28 day prior C1D1 must recover fully side effect treatment prior begin study treatment . 6 . Women childbearing potential must negative pregnancy test within 7 day initiation dosing must agree use acceptable method birth control study drug 3 month last dose . Women nonchildbearing potential may include either surgically sterile postmenopausal ≥1 year . Men childbearing potential must also agree use acceptable method birth control study drug . 7 . ECOG performance status 0 1 8 . Adequate hematologic , hepatic , renal function ( absolute neutrophil count ≥1.0 x 109/L , Hgb &gt; 9 g/dL , platelet count ≥50 x 109/L , AST/ALT ≤2.5x ULN , creatinine ≤1.5x ULN ) 9 . Willing able provide write informed consent prior study related procedure comply study requirement 1 . Investigational drug use within 28 day first dose PLX3397 2 . History clinical evidence central nervous system , meningeal , epidural disease include brain metastasis 3 . Patients another active cancer [ exclude basal cell carcinoma cervical intraepithelial neoplasia ( cervical carcinoma situ ) melanoma situ ] . Prior history cancer allow , long active disease within prior 5 year . 4 . Patients uncontrolled intercurrent illness , active uncontrolled infection , fever &gt; 38.5˚C ( due tumor fever ) C1D1 5 . Refractory nausea vomiting , malabsorption , biliary shunt , significant bowel resection would preclude adequate absorption 6 . Patients serious illness , medical condition , medical history include abnormal laboratory result , investigator 's opinion would likely interfere patient 's participation study , interpretation result 7 . Women childbearing potential pregnant breast feed 8 . QTc ≥450 msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
</DOC>